Smiths Acquisition Weighs On ICU Medical’s Profitability, Shares Fall
ICU Medical Inc (NASDAQ:ICUI) reported Q2 sales of $561 million, up 75% Y/Y, due to Smiths Medical’s acquisition, and missing…
Hilton Grand Vacations Shares Slide On Q2 Earnings Miss
Hilton Grand Vacations Inc (NYSE:HGV) reported second-quarter FY22 sales growth of 183.8% year-on-year to $948 million, missing the consensus of $951.36…
Planet Fitness Shares Slide On Q2 Revenue Miss
Planet Fitness Inc (NYSE:PLNT) reported second-quarter FY22 sales growth of 63.5% year-on-year to $224.4 million, missing the consensus of $230.14 million.…
Sysco’s Q4 Earnings Exceeds Street Expectations
Sysco Corp (NYSE:SYY) reported fourth-quarter FY22 sales growth of 17.5% year-on-year to $19 billion, beating the consensus of $18.21 billion. The…
Emerson Electric Reports Q3 Sales Growth Of 7%, Raises FY22 EPS Guidance
Emerson Electric Co (NYSE:EMR) reported third-quarter FY22 net sales growth of 7% year-over-year to $5 billion, missing the consensus of $5.12…
Workhorse Group Shares Plummet Post Q2 Results
Workhorse Group Inc (NASDAQ:WKHS) reported second-quarter FY22 sales of $12.6 thousand versus $1.2 million last year due to a decrease in…
EVgo Reports Mixed Q2 Results
EVgo Inc (NASDAQ:EVGO) reported second-quarter FY22 sales growth of 90% year-on-year to $9.08 million, missing the consensus of $10.81 million. EVgo’s…
Ralph Lauren’s Q1 Highlights: Earnings Beat, Margin Pressure, Higher Inventory & More
Ralph Lauren Corp (NYSE:RL) reported first-quarter FY23 sales growth of 8% year-on-year, to $1.49 billion, beating the consensus of $1.41 billion.…
Tennant Company Expects FY22 Net Sales, Net Income Per Share, Adj. EBITDA To Be Near Lower End Of Guidance Range
We are confirming our full-year 2022 guidance detailed below. However, we now expect net sales, net income per share and Adjusted EBITDA to be near the lower end of the range as we factor in foreign currency
Verona Pharma’s Lung Disease Candidate Cuts COPD Exacerbations By 42%
Verona Pharma plc (NASDAQ:VRNA) has announced topline results from Phase 3 ENHANCE-2 of nebulized ensifentrine for the maintenance treatment of chronic…